CHMP Endorses Merck's Kidney Cancer Drug for Two Indications

Merck (MRK) announced that EMA’s Committee for Medicinal Products for Human Use (“CHMP”) recommended granting conditional approval to its oral HIF-2α inhibitor, Welireg (belzutifan), for use in two indications associated with renal cell carcinoma (“RCC”).The CHMP recommended Welireg to treat adult patients with von Hippel-Lindau (“VHL”) disease who require therapy for associated RCC, central nervous system hemangioblastomas or pancreatic neuroendocrine tumors, not requiring immediate surgery. This committee ...